Literature DB >> 27741175

Factors Associated With Recurrence After Surgical Resection in Women With Intravenous Leiomyomatosis.

Xin Yu1, Guorui Zhang, Jinghe Lang, Bao Liu, Dachun Zhao.   

Abstract

OBJECTIVE: To analyze the recurrence features and prognostic factors of patients with intravenous leiomyomatosis after complete tumor resection.
METHODS: We conducted a retrospective study of 58 patients with intravenous leiomyomatosis with follow-up data out of 75 patients treated from September 2005 to September 2015 and an analysis of postoperative recurrence features and prognostic factors.
RESULTS: The average patient age was 45.4 years. The preoperative diagnosis rate was low. Among the 58 total patients, 31 had tumors that spread to the inferior vena cava and heart. During the median follow-up of 11.5 months, recurrence occurred in 18 patients at a rate of 31.0% (95% confidence interval 19.0-43.0%). Recurrence was associated with the preoperative tumor extent, and large vein involvement (16/31 compared with 2/27, P=.02) was a risk factor for postoperative recurrence. Postoperative recurrence was not associated with age (1/10 in 50 years or older compared with 17/48 younger than 50 years, P=.35), involvement of the heart (10/22 compared with 8/36, P=.28), resection of the uterus (16/51 compared with 2/7, P=.84) or bilateral ovaries (15/40 compared with 3/18, P=.65) with complete tumor removal, the choice of one-stage or two-stage surgery (11/45 for one-stage surgery compared with 7/13 for two-stage surgery, P=.20), postoperative antiestrogen hormone therapy (10/24 compared with 8/34, P=.53), or the hormone therapy duration (5/17 in the over-6-months group compared with 13/41 in the under-6-months group, P=.81).
CONCLUSION: The postoperative recurrence rate of intravenous leiomyomatosis was high, and large vein involvement was associated with an increased risk of recurrence. Continued postoperative follow-up is important. Neither resection of bilateral ovaries nor postoperative hormone therapy was associated with recurrence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27741175     DOI: 10.1097/AOG.0000000000001718

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  Management and prognosis comparison between incidental and nonincidental intravenous leiomyomatosis: a retrospective single-center real-life experience.

Authors:  Peipei Shi; Hongyang Xiao; Hua Li; Wenbin Tang; Aimin Ren; Li Ma; Ruiqin Tu; Sheng Yin; Jiarong Zhang
Journal:  Ann Transl Med       Date:  2022-05

2.  Intravenous leiomyomatosis: the first reported case of intraoperative intracaval embolisation of tumour to the right atrium.

Authors:  Gillian A Corbett; Catherine O'Gorman; Waseem Kamran
Journal:  BMJ Case Rep       Date:  2020-03-12

3.  Clinical analysis of uterine intravenous leiomyomatosis: A retrospective study of 260 cases.

Authors:  Jing Peng; Fangfang Zhong; Yuemeng Zhu; Mingxing Zhang; Meng Zhang; Chong Lu; Yumeng Wang; Xingling Qi; Congwen Wang; Guiling Li
Journal:  J Obstet Gynaecol Res       Date:  2021-09-15       Impact factor: 1.697

4.  Identification of Novel Serum Metabolic Biomarkers as Indicators in the Progression of Intravenous Leiomyomatosis: A High Performance Liquid Chromatography-Tandem Mass Spectrometry-Based Study.

Authors:  Zhitong Ge; Penghui Feng; Zijuan Zhang; Jianchu Li; Qi Yu
Journal:  Front Cell Dev Biol       Date:  2021-07-08

5.  Aberrant uterine leiomyomas with extrauterine manifestation: intravenous leiomyomatosis and benign metastasizing leiomyomas.

Authors:  Yoo-Na Kim; Kyung Jin Eoh; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  Obstet Gynecol Sci       Date:  2018-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.